This is a promotional website intended for UK healthcare professionals.

Colobreathe® (colistimethate sodium) Prescribing Information can be found here.
Adverse Event Reporting Information can be found at the end of this page.

About Essential Pharma
Menu

Effective Pseudomonas aeruginosa treatment for patients with cystic fibrosis (CF)1,2

What is Colobreathe®?

Colobreathe® is a dry powder inhaler that is indicated for the management of Pseudomonas aeruginosa infections in patients with CF, aged 6 years and older.2

Colobreathe®’s active substance, colistimethate sodium, is an antibiotic from the polymyxin group. Polymyxins destroy Gram-negative bacterial cells such as Pseudomonas aeruginosa. They do this by causing damage to the bacterial cell membranes which ultimately leads to cell death.2

Pulmonary infection with P. aeruginosa is the leading cause of morbidity and mortality in patients with CF.3

Colobreathe® offers a convenient treatment regimen for people with CF

  • Colobreathe® is a simple regimen; treatment may be continued for as long as the physician considers that the patient is obtaining clinical benefit2
  • Colobreathe®’s Turbospin® inhaler device requires minimal cleaning and maintenance1,4
  • One capsule is inhaled twice-daily (the dose interval should be as close as possible to 12 hours), with each capsule delivering 1,662,500 IU colistimethate sodium2
  • Each pack contains 56 capsules, providing your patients with 28 days of medication supply2
Packaging may vary
For more information on dosing and administration please consult the Summary of Product Characteristics.
Learn more about efficacy and safety profile of Colobreathe®

CF, cystic fibrosis; IU, international unit.

References:
1. Schuster A, Haliburn C, Döring G, et al. Thorax. 2013;68:344–350.
2. Colobreathe® Summary of Product Characteristics. Available here.
3. Moradali MF, Ghods S, Rehm BH. Front Cell Infect Microbiol. 2017;7:39.
4. Colobreathe® Patient Information Leaflet. Available here.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for the MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Essential Pharma on +44 (0) 1423 850700 or at EssentialpharmaUK@EU.ProPharmaGroup.com.

Essential Pharma Ltd, 8A Crabtree Road, Egham, Surrey, TW20 8RN, United Kingdom
Colobreathe® is a registered trademark of Essential Pharma. Copyright © 2026 Essential Pharma
MAT-COL-GB-0003-1224 May 2025

crossmenu